Document is current
Any future updates will be listed below
-
Authors
Huang, Jianfeng https://orcid.org/0000-0002-4576-2581
Nittala, Muneeswar Gupta
Corradetti, Giulia
Chung, Yu-Chien https://orcid.org/0000-0003-4745-8601
Quarta, Alberto
Abbasgholizadeh, Rouzbeh
Soylu, Ceren
Chujo, Shinichiro
Velaga, Swetha Bindu https://orcid.org/0000-0002-4637-6914
Sadda, Srinivas R. https://orcid.org/0000-0002-4939-3306
- License Information
-
More Information
Article History
Received: 3 January 2026
Revised: 11 May 2026
Accepted: 9 June 2026
First Online: 19 June 2026
Competing interests
: Dr. Srinivas R. Sadda has the following disclosures: Consultant (C): Roche/Genentech, Regeneron, Allergan/Abbvie, Novartis, Amgen, Alnylam, Alkeus, Neurotech, 4DMT, Alexion, Nanoscope, Biogen, Samsung Bioepis, Apellis, Astellas, ONL Therapeutics, Optos, Oxurion, Pfizer, Boerhinger Ingelheim, Surrozen, ArrowheadPharma, Eyestem, Topcon, Notal, Heidelberg Engineering, iCare; Recipient (R): Topcon Medical Systems Inc. Heidelberg Engineering, Nidek Incorporated, Novartis Pharma AG; Roche; Financial Support (F): Topcon, Carl Zeiss Meditec, Heidelberg Engineering, Optos Inc., Nidek, iCare/Centervue, Intalight. Other authors report no conflicts of interest.
